GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Novelion Therapeutics Inc (STU:QLTA) » Definitions » Debt-to-Equity

Novelion Therapeutics (STU:QLTA) Debt-to-Equity : -3.02 (As of Mar. 2019)


View and export this data going back to . Start your Free Trial

What is Novelion Therapeutics Debt-to-Equity?

Novelion Therapeutics's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2019 was €318.1 Mil. Novelion Therapeutics's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2019 was €0.0 Mil. Novelion Therapeutics's Total Stockholders Equity for the quarter that ended in Mar. 2019 was €-105.3 Mil. Novelion Therapeutics's debt to equity for the quarter that ended in Mar. 2019 was -3.02.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Novelion Therapeutics's Debt-to-Equity or its related term are showing as below:

STU:QLTA's Debt-to-Equity is not ranked *
in the Biotechnology industry.
Industry Median: 0.15
* Ranked among companies with meaningful Debt-to-Equity only.

Novelion Therapeutics Debt-to-Equity Historical Data

The historical data trend for Novelion Therapeutics's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Novelion Therapeutics Debt-to-Equity Chart

Novelion Therapeutics Annual Data
Trend Dec09 Dec10 Dec11 Dec12 Dec13 Dec14 Dec15 Dec16 Dec17 Dec18
Debt-to-Equity
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - 1.66 17.31 -3.92

Novelion Therapeutics Quarterly Data
Jun14 Sep14 Dec14 Mar15 Jun15 Sep15 Dec15 Mar16 Jun16 Sep16 Dec16 Mar17 Jun17 Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19
Debt-to-Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -21.67 -6.52 -4.39 -3.92 -3.02

Competitive Comparison of Novelion Therapeutics's Debt-to-Equity

For the Biotechnology subindustry, Novelion Therapeutics's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Novelion Therapeutics's Debt-to-Equity Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Novelion Therapeutics's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Novelion Therapeutics's Debt-to-Equity falls into.


Novelion Therapeutics Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Novelion Therapeutics's Debt to Equity Ratio for the fiscal year that ended in Dec. 2018 is calculated as

Debt to Equity=Total Debt / Total Stockholders Equity
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Total Stockholders Equity
=(306.324 + 0) / -78.108
=-3.92

Novelion Therapeutics's Debt to Equity Ratio for the quarter that ended in Mar. 2019 is calculated as

Debt to Equity=Total Debt / Total Stockholders Equity
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Total Stockholders Equity
=(318.116 + 0) / -105.27
=-3.02

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Novelion Therapeutics  (STU:QLTA) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

Novelion Therapeutics Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of Novelion Therapeutics's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Novelion Therapeutics (STU:QLTA) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Novelion Therapeutics Inc (STU:QLTA) » Definitions » Debt-to-Equity
Comparable Companies
DFFN TSXV:KLY TSXV:QPT ASX:PTX ROCO:4197 XSAT:WNT PTIX IST:RTALB TROV NOVN MATN LSE:TRX ASX:NYR ATOS TSXV:BCT JAGX TSX:CTX ROCO:6744 ACHV EMBI
Traded in Other Exchanges
N/A
Address
c/o Norton Rose Fulbright, 1800 West Georgia Street, Suite 510, Vancouver, BC, CAN, V6B 0M3
Website
http://www.novelion.com
Headquartered in Vancouver, Canada, QLT is a biotechnology company that researches and develops products used to treat conditions of the eye. After a recent board change, QLT divested its only marketed product, a laser treatment called Visudyne for the treatment of wet age-related macular degeneration and subfoveal choroidal neovascularization. QLT also earns royalty payments on other certain previously divested products. Following recent pipeline changes, the company currently has one product in development for two rare eye conditions.